Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Classical Hallucinogens As Antidepressant Drugs: A Cautionary Approach

Author(s): Rafael G. dos Santos*, Giordano Novak Rossi, Jaime E. C. Hallak, Dost Öngür and Serdar M. Dursun

Volume 21, Issue 1, 2023

Published on: 08 November, 2022

Page: [10 - 12] Pages: 3

DOI: 10.2174/1570159X20666220425133824

Price: $65

« Previous Next »
[1]
Dos Santos, R.G.; Hallak, J.E.C. Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci. Biobehav. Rev., 2020, 108, 423-434.
[http://dx.doi.org/10.1016/j.neubiorev.2019.12.001] [PMID: 31809772]
[2]
Gasser, P.; Holstein, D.; Michel, Y.; Doblin, R.; Yazar-Klosinski, B.; Passie, T.; Brenneisen, R. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J. Nerv. Ment. Dis., 2014, 202(7), 513-520.
[http://dx.doi.org/10.1097/NMD.0000000000000113] [PMID: 24594678]
[3]
Grob, C.S.; Danforth, A.L.; Chopra, G.S.; Hagerty, M.; McKay, C.R.; Halberstadt, A.L.; Greer, G.R. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry, 2011, 68(1), 71-78.
[http://dx.doi.org/10.1001/archgenpsychiatry.2010.116] [PMID: 20819978]
[4]
Griffiths, R.R.; Johnson, M.W.; Carducci, M.A.; Umbricht, A.; Richards, W.A.; Richards, B.D.; Cosimano, M.P.; Klinedinst, M.A. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol., 2016, 30(12), 1181-1197.
[http://dx.doi.org/10.1177/0269881116675513] [PMID: 27909165]
[5]
Ross, S.; Bossis, A.; Guss, J.; Agin-Liebes, G.; Malone, T.; Cohen, B.; Mennenga, S.E.; Belser, A.; Kalliontzi, K.; Babb, J.; Su, Z.; Corby, P.; Schmidt, B.L. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol., 2016, 30(12), 1165-1180.
[http://dx.doi.org/10.1177/0269881116675512] [PMID: 27909164]
[6]
Palhano-Fontes, F.; Barreto, D.; Onias, H.; Andrade, K.C.; Novaes, M.M.; Pessoa, J.A.; Mota-Rolim, S.A.; Osório, F.L.; Sanches, R.; Dos Santos, R.G.; Tófoli, L.F.; de Oliveira Silveira, G.; Yonamine, M.; Riba, J.; Santos, F.R.; Silva-Junior, A.A.; Alchieri, J.C.; Galvão-Coelho, N.L.; Lobão-Soares, B.; Hallak, J.E.C.; Arcoverde, E.; Maia-de-Oliveira, J.P.; Araújo, D.B. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol. Med., 2019, 49(4), 655-663.
[http://dx.doi.org/10.1017/S0033291718001356] [PMID: 29903051]
[7]
Dos Santos, R.G.; Osório, F.L.; Rocha, J.M.; Rossi, G.N.; Bouso, J.C.; Rodrigues, L.S.; de Oliveira Silveira, G.; Yonamine, M.; Hallak, J.E.C. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: A pilot, proof-of-concept, randomized, placebo-controlled trial. J. Clin. Psychopharmacol., 2021, 41(5), 540-550.
[http://dx.doi.org/10.1097/JCP.0000000000001428] [PMID: 34166299]
[8]
Carhart-Harris, R.L.; Bolstridge, M.; Rucker, J.; Day, C.M.J.; Erritzoe, D.; Kaelen, M.; Bloomfield, M.; Rickard, J.A.; Forbes, B.; Feilding, A.; Taylor, D.; Pilling, S.; Curran, V.H.; Nutt, D.J. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry, 2016, 3(7), 619-627.
[http://dx.doi.org/10.1016/S2215-0366(16)30065-7] [PMID: 27210031]
[9]
Sanches, R.F.; de Lima Osório, F.; Dos Santos, R.G.; Macedo, L.R.; Maia-de-Oliveira, J.P.; Wichert-Ana, L.; de Araujo, D.B.; Riba, J.; Crippa, J.A.; Hallak, J.E. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. J. Clin. Psychopharmacol., 2016, 36(1), 77-81.
[http://dx.doi.org/10.1097/JCP.0000000000000436] [PMID: 26650973]
[10]
Davis, A.K.; Barrett, F.S.; May, D.G.; Cosimano, M.P.; Sepeda, N.D.; Johnson, M.W.; Finan, P.H.; Griffiths, R.R. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 2021, 78(5), 481-489.
[http://dx.doi.org/10.1001/jamapsychiatry.2020.3285] [PMID: 33146667]
[11]
Carhart-Harris, R.; Giribaldi, B.; Watts, R.; Baker-Jones, M.; Murphy-Beiner, A.; Murphy, R.; Martell, J.; Blemings, A.; Erritzoe, D.; Nutt, D.J. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med., 2021, 384(15), 1402-1411.
[http://dx.doi.org/10.1056/NEJMoa2032994] [PMID: 33852780]
[12]
Martinotti, G.; Santacroce, R.; Pettorruso, M.; Montemitro, C.; Spano, M.C.; Lorusso, M.; di Giannantonio, M.; Lerner, A.G. Hallucinogen persisting perception disorder: Etiology, clinical features, and therapeutic perspectives. Brain Sci., 2018, 8(3), 47.
[http://dx.doi.org/10.3390/brainsci8030047] [PMID: 29547576]
[13]
Schifano, F.; Chiappini, S.; Miuli, A.; Corkery, J.M.; Scherbaum, N.; Napoletano, F.; Arillotta, D.; Zangani, C.; Catalani, V.; Vento, A.; Pettorruso, M.; Martinotti, G.; Massimo, D.G.; Guirguis, A. New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. Exp. Neurol., 2021, 339, 113638.
[http://dx.doi.org/10.1016/j.expneurol.2021.113638] [PMID: 33571533]
[14]
Martinotti, G.; De Risio, L.; Vannini, C.; Schifano, F.; Pettorruso, M.; Di Giannantonio, M. Substance-related exogenous psychosis: A postmodern syndrome. CNS Spectr., 2021, 26(1), 84-91.
[http://dx.doi.org/10.1017/S1092852920001479] [PMID: 32580808]
[15]
Mason, N.L.; Kuypers, K.P.C.; Müller, F.; Reckweg, J.; Tse, D.H.Y.; Toennes, S.W.; Hutten, N.R.P.W.; Jansen, J.F.A.; Stiers, P.; Feilding, A.; Ramaekers, J.G. Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology, 2020, 45(12), 2003-2011.
[http://dx.doi.org/10.1038/s41386-020-0718-8] [PMID: 32446245]
[16]
Palhano-Fontes, F.; Andrade, K.C.; Tofoli, L.F.; Santos, A.C.; Crippa, J.A.; Hallak, J.E.; Ribeiro, S.; de Araujo, D.B. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One, 2015, 10(2), e0118143.
[http://dx.doi.org/10.1371/journal.pone.0118143] [PMID: 25693169]
[17]
de Almeida, R.N.; Galvão, A.C.M.; da Silva, F.S.; Silva, E.A.D.S.; Palhano-Fontes, F.; Maia-de-Oliveira, J.P.; de Araújo, L.B.; Lobão-Soares, B.; Galvão-Coelho, N.L. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front. Psychol., 2019, 10, 1234.
[http://dx.doi.org/10.3389/fpsyg.2019.01234] [PMID: 31231276]
[18]
Galvão-Coelho, N.L.; de Menezes Galvão, A.C.; de Almeida, R.N.; Palhano-Fontes, F.; Campos Braga, I.; Lobão Soares, B.; Maia-de-Oliveira, J.P.; Perkins, D.; Sarris, J.; de Araujo, D.B. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J. Psychopharmacol., 2020, 34(10), 1125-1133.
[http://dx.doi.org/10.1177/0269881120936486] [PMID: 32648790]
[19]
Phelps, J.; Shah, R.N.; Lieberman, J.A. The rapid rise in investment in psychedelics-Cart before the horse. JAMA Psychiatry, 2022, 79(3), 189-190.
[http://dx.doi.org/10.1001/jamapsychiatry.2021.3972] [PMID: 35044453]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy